Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Stock Review for Biotech's Investors -- Sage Therapeutics, Sarepta Therapeutics, Sierra Oncology, and Sorrento Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on SAGE, SRPT, SRRA, and SRNE which can be accessed for free by signing up to www.wallstequities.com/registration....

SRNE : 9.13 (+4.34%)
SRPT : 64.37 (+0.58%)
SRRA : 3.13 (+7.93%)
SAGE : 166.27 (+2.40%)
Sierra Oncology to host Program Update in New York on February 27th

Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th -

SRRA : 3.13 (+7.93%)
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit

- "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston -

SRRA : 3.13 (+7.93%)
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit

"Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston -

SRRA : 3.13 (+7.93%)
Sierra Oncology (SRRA) in Focus: Stock Moves 10.5% Higher

Sierra Oncology (SRRA) was a big mover last session, as the company saw its shares rise nearly 11% on the day.

SRRA : 3.13 (+7.93%)
CSRMY : 16.6500 (+4.06%)
Sierra Oncology Reports Third Quarter Results

- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK -- On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 3.13 (+7.93%)
Sierra Oncology Reports Third Quarter Results

Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 3.13 (+7.93%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 3.13 (+7.93%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 3.13 (+7.93%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

"Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 3.13 (+7.93%)
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine...

SRRA : 3.13 (+7.93%)
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

- SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine...

SRRA : 3.13 (+7.93%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 3.13 (+7.93%)
CLVS : 55.84 (+3.12%)
EPZM : 18.30 (+0.83%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 3.13 (+7.93%)
CLVS : 55.84 (+3.12%)
EPZM : 18.30 (+0.83%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 3.13 (+7.93%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 3.13 (+7.93%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 3.13 (+7.93%)
Sierra Oncology to Present at the 2017 BIO Investor Forum

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 -

SRRA : 3.13 (+7.93%)
Sierra Oncology to Present at the 2017 BIO Investor Forum

"Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 -

SRRA : 3.13 (+7.93%)
Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY

Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development -

SRRA : 3.13 (+7.93%)

Van Meerten Stock Picks

Nvidia - My Favorite S\&P 500 Large Cap Stock
$NVDA Summary96% technical by signals.
NVDA +6.79
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 -0.63% ) this morning are down -0.60% as the 10-year T-note yield moves above 2.90%. U.S. government debt prices are under pressure on supply concerns as the Treasury gets ready to auction... Read More

Chart of the Day

Abiomed (ABMD) is the Barchart Chart of the Day.  The medical instrument company has a Trend Spotter buy signal, a Weighted Alpha o 139.67+ and gained 132.53% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures are trading 1 to 2 cents higher this morning. They were fractionally lower on Friday, while nearby March was 1.52% higher on the week. US Export commitments of corn are now 69% of the full year USDA forecast. Last year at this time was 7...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.